Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Professional Research Report 2025

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Professional Research Report 2025

Research Summary

Duchenne Muscular Dystrophy (DMD) drugs are medications specifically developed to address the symptoms and underlying causes of DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. These drugs may include corticosteroids, which can help slow muscle deterioration and delay the loss of function. Emerging treatments encompass gene therapies designed to correct or replace the faulty dystrophin gene responsible for DMD, potentially offering more targeted and transformative approaches to managing the disease. DMD drugs aim to improve muscle function, mobility, and overall quality of life for individuals affected by this condition, representing significant advancements in the medical management of DMD.

According to DIResearch's in-depth investigation and research, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global  manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Duchenne Muscular Dystrophy (DMD) Therapeutics. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Duchenne Muscular Dystrophy (DMD) Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Duchenne Muscular Dystrophy (DMD) Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics Include:

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy (DMD) Therapeutics Product Segment Include:

Exondys

Emflaza

Translarna

Duchenne Muscular Dystrophy (DMD) Therapeutics Product Application Include:

Hospitals

Clinics

Home Care

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry PESTEL Analysis

Chapter 3: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Porter’s Five Forces Analysis

Chapter 4: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Major Regional Market Size and Forecast Analysis

Chapter 5: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Passenger Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources